CO6331336A2 - Derivados de 4,5-dihidro-oxazol-2-ilo - Google Patents

Derivados de 4,5-dihidro-oxazol-2-ilo

Info

Publication number
CO6331336A2
CO6331336A2 CO10148408A CO10148408A CO6331336A2 CO 6331336 A2 CO6331336 A2 CO 6331336A2 CO 10148408 A CO10148408 A CO 10148408A CO 10148408 A CO10148408 A CO 10148408A CO 6331336 A2 CO6331336 A2 CO 6331336A2
Authority
CO
Colombia
Prior art keywords
halogen
disorders
lower alkyl
chr
substituted
Prior art date
Application number
CO10148408A
Other languages
English (en)
Inventor
Guido Galley
Annick Goergler
Roger David Norcross
Zbinden Katrin Groebke
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41066683&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6331336(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO6331336A2 publication Critical patent/CO6331336A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/28—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

La invención se está relacionada con compuestos de fórmula en el queR1 es hidrógeno, alquilo inferior, alcoxi inferior, alquilo inferior sustituido por halógeno, alcoxi inferior sustituido por halógeno, halógeno, ciano, nitro, hidroxi, C(O)O-alquilo inferior, S(O)2-alquilo inferior, C(O)OCH2- fenilo, OCH2-fenilo, tetrazol-1-ilo, fenilo opcionalmente sustituido por halógeno, o es feniloxi opcionalmente sustituido por halógeno, o es bencilo opcionalmente sustituido por halógeno o es benciloxi opcionalmente sustituido por halógeno, en el que los sustituyentes para n> pueden ser el mismo o diferente;X es -O-(CH2)2-, -O-CHR''-CH2-, -O-CH2-CHR', -O-CR''2-CH2-, -(CH2)2-CHR', -CHR'-(CH2)2-, -CR''2-(CH2)2-,-CH2-CHR'-CH2-, -CH2-CR''2-CH2-, -CHR''-O-CH2-, -CH2-O-CH2-, -CR''2-O-CH2-, -CF2(CH2)2-, -CR''2-CH2-, SiR''2-(CH2)2-, -S-(CH2)2-, -S(O)2-(CH2)2-, -(CH2)4-, -CH2-O-(CH2)2-,para m siendo 0, 1, 2 o 3;R' es alquilo inferior, alcoxi inferior o alquilo inferior sustituido por halógeno;R'' es alquilo inferior o alquilo inferior sustituido por halógeno;R2 es hidrógeno o alquilo inferior;Y es arilo, cicloalquilo o heteroarilo;n es 1, 2 o 3;o una sal de adición ácida farmacéuticamente adecuada.Los compuestos descritos en la presente fórmula I pueden utilizarse para el tratamiento de enfermedades relacionadas con la función biológica de los receptores asociados a aminas traza, cuyas enfermedades son la depresión, trastornos de ansiedad, trastorno bipolar, trastorno de déficit de atención por hiperactividad, trastornos relacionados con el estrés, trastornos psicóticos, esquizofrenia, enfermedades neurológicas, enfermedad de Parkinson, trastornos neurodegenerativos, enfermedad de Alzheimer, epilepsia, rnigraña, abuso de sustancias y trastornos metabólicos, trastornos alimenticios, diabetes, complicaciones diabéticas, obesidad, dislipidemia, trastornos de consumo de energía y asimilación, trastornos y disfunción de la homeostasis de la temperatura corporal, trastornos del sueño y del ritmo circadiano, y trastornos cardiovasculares.
CO10148408A 2008-07-24 2010-11-25 Derivados de 4,5-dihidro-oxazol-2-ilo CO6331336A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08161060 2008-07-24

Publications (1)

Publication Number Publication Date
CO6331336A2 true CO6331336A2 (es) 2011-10-20

Family

ID=41066683

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10148408A CO6331336A2 (es) 2008-07-24 2010-11-25 Derivados de 4,5-dihidro-oxazol-2-ilo

Country Status (22)

Country Link
US (2) US20100041686A1 (es)
EP (1) EP2321287B1 (es)
JP (1) JP5547187B2 (es)
KR (1) KR101307007B1 (es)
CN (1) CN102083805A (es)
AR (1) AR072876A1 (es)
AU (1) AU2009273324A1 (es)
BR (1) BRPI0916363A2 (es)
CA (1) CA2728480A1 (es)
CL (1) CL2011000137A1 (es)
CO (1) CO6331336A2 (es)
CR (1) CR11843A (es)
EC (1) ECSP11010782A (es)
ES (1) ES2556633T3 (es)
IL (1) IL209423A0 (es)
MA (1) MA32486B1 (es)
MX (1) MX2011000464A (es)
PE (1) PE20110215A1 (es)
RU (1) RU2513086C2 (es)
TW (1) TW201008916A (es)
WO (1) WO2010010014A1 (es)
ZA (1) ZA201008657B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY148558A (en) 2008-09-11 2013-04-30 Amgen Inc Spiro-tetracyclic ring compounds as betasecretase modulators and methods of use
US8354441B2 (en) * 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
MX2012010657A (es) 2010-03-15 2013-02-07 Amgen Inc Compuestos de espiro amino-dihidrooxazina y amino-dihidrotiazina como moduladores de beta-secretasa y su uso medico.
CA2791281A1 (en) 2010-03-15 2011-09-22 Amgen Inc. Spiro-tetracyclic ring compounds as beta-secretase modulators
US9132136B2 (en) 2010-08-02 2015-09-15 Hoffmann-La Roche Inc. Pharmaceutical combination
US8673950B2 (en) * 2010-11-02 2014-03-18 Hoffmann-Laroche Inc. Dihydrooxazol-2-amine derivatives
US9346827B2 (en) 2011-02-07 2016-05-24 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use
EP2758406A1 (en) 2011-09-21 2014-07-30 Amgen Inc. Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
US9725469B2 (en) 2012-11-15 2017-08-08 Amgen, Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
EP3757102A1 (en) 2016-03-17 2020-12-30 F. Hoffmann-La Roche AG 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar
JP2019514960A (ja) * 2016-05-04 2019-06-06 パーデュー ファーマ エルピー オキサゾリンシュードダイマー、医薬組成物及びその使用
EP3463359A4 (en) * 2016-06-02 2020-08-26 Purdue Pharma LP SPURENAMINE-ASSOCIATED RECEPTOR-1 AGONISTS AND PARTIAL AGONISTS FOR PAIN MANAGEMENT

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2731471A (en) * 1956-01-17 Nxg hi
US2161938A (en) * 1934-07-31 1939-06-13 Soc Of Chemical Ind Imidazolines
US2457047A (en) * 1946-02-13 1948-12-21 Monsanto Chemicals 2-(2'-thenyl)-4, 5-dihydroimidazoles and process for making the same
US2778836A (en) * 1954-04-02 1957-01-22 Union Chimique Belge Sa Substituted 2-methyl-delta2 imidazolines
US2744910A (en) * 1955-06-27 1956-05-08 Bristol Lab Inc 2-(ortho-benzylbenzyl)-imidazoline and acid addition salts
US2744909A (en) * 1955-06-27 1956-05-08 Bristol Lab Inc 2-(ortho-phenylbenzyl) imidazoline and acid addition salts
US2919274A (en) * 1957-09-17 1959-12-29 Sahyun Melville Amidines
DE1121054B (de) * 1960-11-23 1962-01-04 Merck Ag E Verfahren zur Herstellung eines neuen Imidazolinderivates und dessen Saeureadditionssalzen
DE1150180B (de) * 1962-04-12 1963-06-12 Merck Ag E Mittel zur Vorbehandlung der Haut fuer die Rasur
US3377247A (en) * 1967-04-28 1968-04-09 Dow Chemical Co Antidepressant method
US3586695A (en) * 1968-01-26 1971-06-22 Dow Chemical Co Substituted imidazolinyl indoles
US3577428A (en) * 1969-04-14 1971-05-04 Colgate Palmolive Co 2-amino-4-aryloxyalkyl-4-alkyl-2-oxazolines
BE754935A (fr) * 1969-08-13 1971-02-17 Hoechst Ag 2-(thienyl-3'-amino)-1,3-diazacycloalcenes et leur preparation
US3818094A (en) * 1969-08-28 1974-06-18 Boehringer Sohn Ingelheim Hypotensive pharmaceutical compositions containing certain 2-anilino-1,3-diazacyclopentenes-(2)
US3622579A (en) * 1969-08-28 1971-11-23 Boehringer Sohn Ingelheim Derivatives of 2-anilino-1,3-diazacyclopentene-(2)
US3660423A (en) * 1970-02-13 1972-05-02 Dow Chemical Co 2-(substituted benzyl)methyl-2-imidazolines
GB1333471A (en) * 1971-01-27 1973-10-10 Labaz Imidazoline derivatives and process for preparing the same
US4125620A (en) * 1974-10-01 1978-11-14 Boehringer Ingelheim Gmbh 2-[(2',6'-Disubstituted-phenyl)-imino]-imidazolidines and salts thereof
US3992403A (en) * 1975-05-30 1976-11-16 Schering Corporation 2-Imidazolines and their use as hypoglycemic agents
GB1538097A (en) * 1976-01-26 1979-01-10 Lafon Labor Substituted phenyl-amidines
US4323570A (en) * 1978-11-15 1982-04-06 Beiersdorf Aktiengesellschaft Substituted aminopyrimidines
US4311840A (en) * 1980-11-13 1982-01-19 E. R. Squibb & Sons, Inc. 2,3,6,7-Tetrahydro-2-thioxo-4H-oxazolo[3,2-a]-1,3,5 triazin-4-ones
DE3377061D1 (en) * 1982-06-03 1988-07-21 Hoffmann La Roche Process for the preparation of 1-sulfo-2-oxoazetidine derivatives
DK302185A (da) * 1984-07-05 1986-01-06 Rolland Sa A 2-amino-oxazoliner samt fremgangsmaade til deres fremstilling
US4665095A (en) * 1985-12-11 1987-05-12 Abbott Laboratories Use of 2-[(3,5-dihalo-4-aminobenzyl)]imidazolines to stimulate alpha-1 adrenergic receptors and to treat nasal congestion
GB9425211D0 (en) * 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles
DE19514579A1 (de) * 1995-04-20 1996-10-24 Boehringer Ingelheim Kg Verwendung von alpha¶1¶¶L¶-Agonisten zur Behandlung der Harninkontinenz
US5610174A (en) * 1995-06-02 1997-03-11 Synaptic Pharmaceutical Corporation Use of α1A -selective adrenoceptor agonists for the treatment of urinary incontinence
US5866579A (en) * 1997-04-11 1999-02-02 Synaptic Pharmaceutical Corporation Imidazole and imidazoline derivatives and uses thereof
DE69924717T2 (de) * 1998-04-23 2006-03-09 Takeda Pharmaceutical Co. Ltd. Naphthalene derivate ,ihre herstellung und verwendung
IL147921A0 (en) * 2002-01-31 2002-08-14 Abdulrazik Mohammad A method for treating central nervous system disorders by ocular dosing
CA2581828A1 (en) * 2004-09-24 2006-04-06 Allergan, Inc. 4-(heteroaryl-methyl and substituted heteroaryl-methyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists
ES2338716T3 (es) * 2006-01-27 2010-05-11 F.Hoffmann-La Roche Ag Uso de derivados de 4-imidazol para trastornos del snc.
EP2114906B1 (en) * 2007-02-02 2014-08-06 F. Hoffmann-La Roche AG 2-aminooxazolines as taar1 ligands for cns disorders

Also Published As

Publication number Publication date
ECSP11010782A (es) 2011-02-28
KR101307007B1 (ko) 2013-09-11
BRPI0916363A2 (pt) 2018-05-29
ZA201008657B (en) 2011-10-26
IL209423A0 (en) 2011-01-31
PE20110215A1 (es) 2011-03-31
CN102083805A (zh) 2011-06-01
ES2556633T3 (es) 2016-01-19
WO2010010014A1 (en) 2010-01-28
CL2011000137A1 (es) 2011-07-15
CR11843A (es) 2011-02-16
TW201008916A (en) 2010-03-01
JP5547187B2 (ja) 2014-07-09
US20120165294A1 (en) 2012-06-28
EP2321287A1 (en) 2011-05-18
JP2011528685A (ja) 2011-11-24
RU2513086C2 (ru) 2014-04-20
MX2011000464A (es) 2011-03-01
US20100041686A1 (en) 2010-02-18
MA32486B1 (fr) 2011-07-03
CA2728480A1 (en) 2010-01-28
RU2011104433A (ru) 2012-08-27
AR072876A1 (es) 2010-09-29
EP2321287B1 (en) 2015-11-11
KR20110020936A (ko) 2011-03-03
AU2009273324A1 (en) 2010-01-28

Similar Documents

Publication Publication Date Title
CO6331336A2 (es) Derivados de 4,5-dihidro-oxazol-2-ilo
MX351918B (es) Derivados heterociclicos de amina.
MY176030A (en) Substituted benzamide derivatives
UA98951C2 (ru) 2-аминооксазолины и лекарственное средство, которое их содержит
TW200738645A (en) Use of 4-imidazole derivatives for CNS disorders
TW200833685A (en) Aminomethyl-4-imidazoles
ECSP13013072A (es) Derivados de pirazol
TW200738690A (en) Use of 2-imidazoles for the treatment of CNS disorders
MX2009003887A (es) Aminometil-2-imidazoles con afinidad con los receptores asociados a trazas de amina.
MX354815B (es) Derivados heterociclicos como receptores asociados con las aminas traza (taars).
MX2009005920A (es) Nuevos 2-imidazoles como ligandos para receptores asociados con trazas de amina.
AR092537A1 (es) Derivados de pirazol-carboxamida
MX2016013412A (es) Derivados de morfolina-piridina.
MX2009004617A (es) 2-imidazoles sustituidos como moduladores de los receptores asociados con trazas de amina.
WO2007090720A3 (en) Use of 2-imidazoles for the treatment of cns disorders
MX349738B (es) Derivados de dihidrooxazol-2-amina.
MX2016012624A (es) Derivados de 5-oxa-2-azabiciclo[2.2.2]octan-4-ilo y 5-oxa-2-azabiciclo[2.2.1]heptan-4-ilo como modularores de los receptores asociados a la amina de trazas 1 (taar1).
AR063811A1 (es) 4-imidazoles sustituidos
MX2015005721A (es) Derivados de pirazina.
AR076979A1 (es) 2- aminooxazolinas como ligandos de taar1
TH108796B (th) อนุพันธ์ 4,5-ไดไฮโดร-ออกซาซอล-2-อิล
TH108796A (th) อนุพันธ์ 4,5-ไดไฮโดร-ออกซาซอล-2-อิล
TH103564A (th) 2-อะเซทิดีนมีเธนเอมีน และ 2-ไพร์โรลิดีนมีเธนเอมีน ในฐานะเป็น taar-ลิแกนด์
TH106083A (th) 2-อะมิโนออกซะโซลีนประดิษฐ์ใหม่เป็น taar1 ลิแกนด์

Legal Events

Date Code Title Description
FC Application refused